Hepalink will exit the immune and inflammatory disease drug developer in an acquisition that could reach $1.45bn in size.
Pharmaceutical firm Sanofi agreed yesterday to acquire UK-based monoclonal antibody therapy developer Kymab in a deal sized at up to $1.45bn that will enable pharmaceutical manufacturer Shenzhen Hepalink to exit. The transaction will consist of $1.1bn in cash and up to $350m in milestone payments. It comes after approximately $220m in funding for the company.…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.